使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Hello, everyone. Thank you for joining us, and welcome to Cardinal Health, Inc. first quarter fiscal year 2027 earnings release. (Operator Instructions)
各位好。感謝各位加入我們,歡迎參加 Cardinal Health, Inc. 2027 會計年度第一季財報發布會。(接線員指示)
I will now hand the conference over to David Frost, Vice President, Investor Relations. David, please go ahead.
現在我將把會議交給投資人關係副總裁 David Frost。David,請開始。
David Frost - Vice President, Investor Relations
David Frost - Vice President, Investor Relations
Good morning. Welcome to Cardinal Health's first quarter fiscal 2027 earnings conference call, and thank you for joining us. With me today are Cardinal Health's CEO, Jason Hollar, and our CFO, Aaron Alt. You can find this morning's earnings press release and investor presentation on the Investor Relations section of our website at ir.cardinalhealth.com.
各位早安。歡迎參加 Cardinal Health 2027 會計年度第一季財報電話會議,感謝各位撥冗參與。今天與我一同出席的有 Cardinal Health 執行長 Jason Hollar,以及財務長 Aaron Alt。各位可至我們網站 ir.cardinalhealth.com 的投資人關係專區,查閱今早的財報新聞稿與投資人簡報。
Since we will be making forward-looking statements today, let me remind you that the matters addressed in these statements are subject to risks and uncertainties that could cause our actual results to differ materially from those projected or implied. Please refer to our SEC filings and the forward-looking statement slide at the beginning of our presentation for a description of these risks and uncertainties.
由於我們今天將發表前瞻性陳述,我先提醒各位,這些陳述所涉及事項存在風險與不確定性,可能導致實際結果與所預測或暗示者出現重大差異。關於這些風險與不確定性的說明,請參閱我們向 SEC 提交的文件,以及簡報開頭的前瞻性陳述投影片。
Please note that during our discussion today, the comments will be on a non-GAAP basis, unless specifically called out as GAAP. GAAP to non-GAAP reconciliations for all relevant periods can be found in the supporting schedules attached to our press release. For the Q&A portion of today's call, we kindly ask that you limit questions to one for participants so that we can try and give everyone an opportunity.
請注意,除非特別指出為 GAAP(一般公認會計原則)基礎,否則我們今天討論的評論將以非 GAAP 基礎呈現。所有相關期間的 GAAP 與非 GAAP 調節表,均可在新聞稿所附的補充附表中找到。在今天電話會議的問答環節,我們敬請每位與會者將問題限制為一題,以便我們盡量讓每位都能有提問機會。
With that, I will now turn the call over to Jason.
接下來,我將把電話會議交給 Jason。
Jason Hollar - Chief Executive Officer, Director
Jason Hollar - Chief Executive Officer, Director
Good morning, and thank you for joining us. I am pleased to report a strong start to fiscal '27 with broad-based growth once again across the enterprise. This quarter's results reflect disciplined execution and continued progress against our strategic priorities. We are strengthening our core while investing in the capabilities that will drive growth and long-term value creation. As election results have come into focus, our priorities remain consistent.
各位早安,感謝各位加入我們。我很高興報告,2027 會計年度開局強勁,企業整體再次呈現廣泛的成長。本季成果反映了嚴謹的執行力,以及我們在策略優先事項上的持續進展。我們在強化核心業務的同時,也投資於將推動成長與長期價值創造的能力。隨著選舉結果逐漸明朗,我們的優先事項仍維持一致。
We have a long-standing record of constructive engagement with policymakers on both sides of the aisle. Our focus on better access, lower cost and continued innovation aligns with objectives shared across the political spectrum. Any policy changes will take time, and we would expect to be manageable as we continue to be active in our engagement with government. Our essential role across the healthcare ecosystem positions us to contribute meaningfully to those conversations. And in the meantime, our teams remain focused on delivering for customers and patients every day.
我們長期以來與兩黨政策制定者保持建設性的互動紀錄。我們對於提升可近性、降低成本與持續創新的聚焦,與政治光譜各方共同的目標一致。任何政策變動都需要時間,我們預期在持續積極與政府互動的情況下,相關影響將可控。我們在醫療保健生態系中的關鍵角色,使我們能在這些對話中做出有意義的貢獻。同時,我們的團隊仍專注於每天為客戶與病患交付成果。
Performance demonstrates the value of Cardinal Health's scale, reach and capabilities across the healthcare ecosystem. Recently, we announced the renewal of our largest customer, CVS Health through June 2032. This reflects our long-standing relationship, which predates CVS Health's acquisition of The renewal reinforces the strategic value in ability that the partnership with Cardinal Health brings to CVS' retail pharmacy network, something that will continue beyond the spin-off in 2028.
本季表現展現了 Cardinal Health 在醫療保健生態系中所具備的規模、覆蓋範圍與能力的價值。近期,我們宣布與最大客戶 CVS Health 的合約續約至 2032 年 6 月。這反映了我們長期的合作關係,其可追溯至 CVS Health 收購 The 之前。此次續約強化了與 Cardinal Health 的合作為 CVS 零售藥局網路所帶來的策略價值與能力,而這項合作也將在 2028 年分拆後持續延伸。
Just as importantly, when combined with our other recent significant renewals, it provides a steady foundation for continued investment in the business and supports the sustained execution of our growth strategies. In Global Medical Products and Distribution, performance was stable, notwithstanding global volatility as the team continued to execute the improvement plan, including actions to optimize the network, improve efficiency and grow Cardinal Health brand. We remain encouraged by our progress while recognizing there's more opportunity ahead to continue to optimize this segment.
同樣重要的是,若再結合我們近期其他重大續約,這為我們持續投資業務提供了穩健的基礎,並支持我們成長策略的持續落實。在全球醫療產品與配送(Global Medical Products and Distribution)方面,儘管全球波動存在,團隊仍持續執行改善計畫(包括優化網路、提升效率以及擴大 Cardinal Health 品牌),使得表現保持穩定。我們對進展仍感到鼓舞,同時也認知到未來仍有更多機會可持續優化此業務部門。
Our other growth businesses also delivered positive results, supported by healthy demand from underlying secular trends, the investments we've made to build differentiated positions and a firm focus on integrating the acquisitions in that home. Taken together, the quarter's performance and our visibility into the balance of the year give us confidence to raise our fiscal '27 outlook, which Aaron will walk through in more detail.
我們其他成長型業務也交出正向成果,受惠於長期結構性趨勢帶動的健康需求、我們為建立差異化地位所做的投資,以及對整合相關收購案的堅定聚焦。綜合而言,本季表現以及我們對本年度剩餘期間的能見度,使我們有信心上調 2027 會計年度展望,Aaron 將進一步說明細節。
With that, I'll turn the call over to Aaron.
接下來我把電話會議交給 Aaron。
Aaron Alt - Chief Financial Officer
Aaron Alt - Chief Financial Officer
Good morning. The Cardinal Health team delivered a strong first quarter, above and below the line on the income statement and with respect to cash flow. Our performance was characterized by strong demand across the enterprise led by our Pharmaceutical and Specialty Solutions segment and our other operating businesses. Demand was matched by good operational execution by all of our teams. Given our Q1 delivery, we are pleased to raise our fiscal 2027 EPS guidance to $12.80 to $13 from the previous range of $12.40 to $12.60.
各位早安。Cardinal Health 團隊在第一季交出強勁成績,無論在損益表的營收端與獲利端,以及現金流表現方面皆然。我們的表現特徵是企業整體需求強勁,其中以藥品與專科解決方案(Pharmaceutical and Specialty Solutions)部門及其他營運業務領軍。需求也由各團隊良好的營運執行相互配合。基於第一季的交付成果,我們很高興將 2027 會計年度 EPS 指引上調至 12.80 至 13.00 美元,先前區間為 12.40 至 12.60 美元。
Moving on to our consolidated first quarter results. Total company revenue grew 5% to $67.5 billion. Consolidated gross profit increased 12% to $2.6 billion. We saw continued strength in our core distribution operations, expanded contributions from our investments in Specialty and gross profit increases from our three growth businesses and others. Consolidated SG&A grew more slowly increasing 9% to $1.6 billion.
接著看合併第一季業績。公司總營收成長 5%,至 675 億美元。合併毛利成長 12%,至 26 億美元。我們看到核心配送營運持續強勁、專科領域投資的貢獻擴大,以及三項成長型業務與其他業務帶來的毛利提升。合併 SG&A(銷售、一般及行政費用)成長較慢,增加 9% 至 16 億美元。
In addition to servicing growing sales, we continue to invest in capabilities for our businesses while also remaining focused on simplification and cost optimization. As gross profit grew faster than SG&A, our operating income grew 17% to $1 billion, achieving that milestone in a quarter for the first time and highlighting the operating leverage we are pursuing.
除了支援成長中的銷售外,我們也持續投資於各項業務能力,同時仍聚焦於簡化與成本最佳化。由於毛利成長快於 SG&A,我們的營業利益成長 17% 至 10 億美元,這是我們首次在單一季度達成該里程碑,也凸顯我們所追求的營運槓桿效益。
Moving below the operating line. Interest and other was $67 million, and our effective tax rate for the first quarter was 18.5%. We are pleased with our progress and continue to focus on building durable improvements to items below the line. After completing a $500 million accelerated share repurchase program during the quarter, our diluted weighted average shares outstanding for the quarter were approximately 233 million shares. All in, our efforts resulted in first quarter diluted earnings per share growth of 28% or $3.26.
接著看營業利益以下項目。利息及其他為 6,700 萬美元,第一季有效稅率為 18.5%。我們對進展感到滿意,並將持續聚焦於在營業利益以下項目建立可持續的改善。本季完成 5 億美元的加速庫藏股回購計畫後,本季稀釋加權平均流通股數約為 2.33 億股。整體而言,我們的努力使第一季稀釋每股盈餘成長 28%,至 3.26 美元。
Let's turn to the specific segment results, beginning with pharma. Segment revenue increased 6% to $62.6 billion driven by growing brand and Specialty sales from existing customers. Specialty grew an 18% clip during the quarter. While the business put up 6% revenue growth in the quarter, we again observed offsetting top line revenue growth dynamics. GLP-1 medications, which continued to grow on pace, drove approximately 500 basis points of revenue growth in the quarter. That was offset in large part by the impact of IRA WAC reductions, which drove 400 basis points revenue headwind year-over-year.
接下來看各部門的具體表現,先從藥品部門開始。部門營收成長 6% 至 626 億美元,主要由既有客戶的品牌藥與專科銷售成長所帶動。專科業務本季以 18% 的增速成長。雖然本季營收成長 6%,我們再次觀察到營收端存在相互抵銷的動態。GLP-1 藥物持續以既有速度成長,為本季營收成長貢獻約 500 個基點。但這在很大程度上被 IRA WAC(通膨削減法案下的批發取得成本)下調的影響所抵銷,該因素使營收年對年形成 400 個基點的逆風。
Segment profit in pharma increased 17% to $783 million. This robust performance reflects healthy contributions from brand, Specialty and our generics program where we continue to observe consistent market dynamics. The core distribution business remains highly resilient, and our strategic sourcing initiatives, notably our Red Oak Sourcing partnership continue to drive significant value.
藥品部門利潤成長 17% 至 7.83 億美元。這項強勁表現反映了品牌藥、專科業務以及我們的學名藥計畫所帶來的健康貢獻;在學名藥方面,我們持續觀察到一致的市場動態。核心配送業務仍具高度韌性,而我們的策略性採購措施(尤其是 Red Oak Sourcing 合作夥伴關係)持續創造顯著價值。
Pharma segment profit also reflected the contribution of our Solaris acquisition which we will lap in the second quarter. MSOs are a part of our broader Specialty strategy, and we remain focused on integration and building the capabilities needed for long-term growth.
藥品部門利潤亦反映了我們收購 Solaris 的貢獻;該項貢獻將在第二季進入年對年比較基期(lap)。MSO 是我們更廣泛專科策略的一部分,我們仍專注於整合並建立長期成長所需的能力。
Now moving to our Global Medical Products and Distribution segment. Segment revenue was roughly flat to prior year at $3.2 billion. This top line result was driven by growth in Cardinal Health brand, offset by lower distribution revenue during the period. Segment profit for GMPD was higher than expected at $33 million for the quarter. We saw a steady improvement in underlying operational performance as our team continued to execute against our GMVD improvement plan.
現在轉到我們的全球醫療產品與配送(Global Medical Products and Distribution, GMPD)部門。部門營收約為32億美元,與去年同期大致持平。此一營收表現主要由Cardinal Health自有品牌成長所帶動,但被本期較低的配送營收所抵銷。本季GMPD部門利潤為3,300萬美元,高於預期。隨著團隊持續落實GMVD改善計畫,我們看到基礎營運表現穩步改善。
We continue to see healthy demand for our Cardinal Health brand products, with U.S. growth in the low to middle single digits for the quarter. Foreign exchange and distribution are headwinds, while on the cost side, modest commodity pressure, primarily in transportation costs was offset by tariff tailwinds.
我們持續看到Cardinal Health自有品牌產品需求健康,本季美國市場成長落在低至中個位數。外匯與配送業務構成逆風;在成本端,主要來自運輸成本的溫和大宗商品壓力,則被關稅帶來的順風所抵銷。
Now let's turn to other, which encompasses our three growth businesses. As we have remarked in the past, these businesses operate in markets aligned with powerful secular trends, including the aging population. The shift to home-based care in complex medical innovation and our results continue to reflect these favorable trends.
接著談「其他」(Other)部門,涵蓋我們三項成長型業務。如同我們過去所提,這些業務所處市場與多項強勁的長期結構性趨勢一致,包括人口老化。居家照護的轉移、複雜醫療創新等趨勢,而我們的業績也持續反映這些有利趨勢。
Revenue for other grew 7% to $1.8 billion, and profit increased 16% to $193 million. With profit growing well above our long-term targets and at more than twice the rate of revenue, our results in Q1 demonstrate our smart growth strategy and action. All three businesses and other delivered revenue and profit growth as we continue to invest in each business' distinct priorities.
「其他」部門營收成長7%至18億美元,利潤成長16%至1.93億美元。利潤成長遠高於我們的長期目標,且增速超過營收的兩倍,我們第一季的結果展現了我們的智慧成長策略與行動力。隨著我們持續投資於各業務的不同優先事項,三項業務皆在「其他」部門實現營收與利潤成長。
Turning to cash on the balance sheet. We ended the first quarter with $5.3 billion of cash after generating $1.6 billion of adjusted free cash flow. We took several actions aligned to our capital allocation framework, including investing $157 million of capital into our business, executing the $500 million share repurchase program I referenced earlier and returning approximately $125 million to shareholders through dividends. We finished the quarter near the midpoint of our targeted leverage range and preserved our strong investment-grade ratings.
接著談資產負債表上的現金。第一季結束時,在創造16億美元調整後自由現金流後,我們的現金餘額為53億美元。我們採取了多項符合資本配置框架的行動,包括投入1.57億美元資本於業務、執行我先前提到的5億美元庫藏股回購計畫,以及透過股利向股東返還約1.25億美元。本季結束時,我們的槓桿水準接近目標區間中點,並維持強勁的投資級評等。
So let's talk about our fiscal 2027 guidance. We are raising our non-GAAP diluted EPS guidance to a new range of $12.80 to $13, up from our prior range of $12.40 to $12.60. This updated guidance represents 17% to 19% growth off our ex turf refund adjusted fiscal '26 EPS of $10.95 and 14% to 15% growth off our reported fiscal '26 EPS of $11.26. This raise reflects the broad-based operating momentum we see across the business and our confidence in continuing to deliver robust profit growth across our operating segments.
接下來談我們2027會計年度的財測指引。我們將非GAAP稀釋每股盈餘(EPS)指引上調至12.80至13.00美元的新區間,先前為12.40至12.60美元。此更新指引相當於在扣除草坪(turf)退款影響後、調整後的2026會計年度EPS 10.95美元基礎上成長17%至19%,以及在已揭露的2026會計年度EPS 11.26美元基礎上成長14%至15%。此次上調反映我們在全公司範圍看到的廣泛營運動能,以及我們對於在各營運部門持續交付強勁利潤成長的信心。
For the Pharma segment, while we continue to expect revenue growth of 3% to 5%, consistent with our original guidance, we have increased our segment profit growth guidance to a range of 10% to 12% from the prior guidance of 8% to 11%. For those wondering about our recent renewals, our original profit guidance for fiscal '27 largely anticipated the financial impact of the CVS renewal. Recall that we provided guidance on the basis of a consistent book of business.
就製藥(Pharma)部門而言,雖然我們仍預期營收成長3%至5%,與原先指引一致,但我們已將部門利潤成長指引由先前的8%至11%上調至10%至12%。對於關心近期續約情況的各位,我們原先對2027會計年度的利潤指引,已在很大程度上預先納入CVS續約的財務影響。請記得,我們提供指引是以一致的業務組合(consistent book of business)為基礎。
Our updated guidance also assumes continued strong demand and performance across our core distribution, generic sourcing and Specialty business. For modeling purposes, following strong growth in the first quarter, we expect earnings growth to moderate in the second and third quarters before strengthening in the fourth quarter to a level modestly below Q1. This is largely a result of timing of the year-over-year impact of customer renewals and lapping the Solaris acquisition.
我們更新後的指引亦假設核心配送、學名藥採購(generic sourcing)與專科(Specialty)業務持續維持強勁需求與表現。就建模而言,在第一季強勁成長之後,我們預期第二與第三季的獲利成長將趨於溫和,並在第四季再度走強,但水準將略低於第一季。這主要是因為客戶續約對年對年影響的時點差異,以及去年同期比較基期包含Solaris收購案。
For the Global Medical Products and Distribution segment, we continue to expect revenue growth of 2% to 4%. While we are not changing our financial guidance for GMPD for the year, we do note that sustained high petroleum costs driven by the ongoing Iran conflict are pushing GMPD segment profit toward the low end of our guidance range of $200 million to $220 million. We remain highly focused on driving long-term profitability through our operational improvement plan in GMPD, and expect the segment's results to be weighted towards the back half of the fiscal year, consistent with historical trends.
就全球醫療產品與配送(GMPD)部門而言,我們仍預期營收成長2%至4%。雖然我們不調整本年度GMPD的財務指引,但我們注意到,受持續的伊朗衝突所推升的高油價,正使GMPD部門利潤更偏向我們2億至2.2億美元指引區間的低端。我們仍高度聚焦於透過GMPD的營運改善計畫推動長期獲利能力,並預期該部門的業績將偏重於會計年度下半年,與歷史趨勢一致。
For modeling purposes, we expect the second quarter to be generally consistent with the Q1 result with sequential quarterly growth for the remainder of the year thereafter. For other, we anticipate revenue growth of 12% to 14%, up from our previous range of 11% to 13%, driven by strong demand across all three operating businesses. We are raising our profit guidance to 17% to 20% growth, up from our prior range of 15% to 18% growth. This reflects the favorable performance and underlying demand we are capturing. We still expect revenue and profit growth to accelerate in the second half of the fiscal year, consistent with our previous guidance.
就建模而言,我們預期第二季整體將大致與第一季結果一致,之後年度剩餘期間將呈現逐季成長。就「其他」部門而言,我們預期營收成長12%至14%,高於先前的11%至13%,主要由三項營運業務全面的強勁需求所帶動。我們也將利潤指引上調至成長17%至20%,高於先前的15%至18%。這反映我們所掌握的有利表現與基礎需求。我們仍預期營收與利潤成長將在會計年度下半年加速,與先前指引一致。
Moving below the operating line, we continue to expect interest and other to be between $240 million and $290 million. We expect our effective tax rate to be in the range of 18.5% to 19.5%, down from our previous guidance of 19% to 20% and reflective of the efforts our teams have made in identifying and executing durable improvements.
在營業利益線以下(below the operating line),我們仍預期利息及其他項目介於2.4億至2.9億美元。我們預期有效稅率將落在18.5%至19.5%區間,低於先前的19%至20%,並反映我們團隊在辨識並落實可持續改善方面所做的努力。
Regarding capital deployment, our anticipated capital expenditure of approximately $700 million remains unchanged. We are actively investing in supply chain modernization, automation, technology and AI infrastructure to drive future productivity.
關於資本運用,我們預期資本支出約7億美元,維持不變。我們正積極投資於供應鏈現代化、自動化、科技與AI基礎設施,以推動未來生產力。
We expect diluted weighted average shares outstanding to be in the range of 231 million to 232 million shares, reflecting the timing of our recently completed $500 million share repurchase program. Finally, we continue to expect adjusted free cash flow to be between $3.5 billion and $4 billion. This robust free cash flow generation provides us with the necessary flexibility to fund organic growth, return capital to our shareholders and pursue accretive targeted M&A.
我們預期稀釋加權平均流通股數將介於2.31億至2.32億股,反映我們近期完成的5億美元庫藏股回購計畫之時點影響。最後,我們仍預期調整後自由現金流介於35億至40億美元。這項強勁的自由現金流創造能力,為我們提供必要的彈性,以支應內生成長、回饋股東資本,並推動具增益性的目標型併購(M&A)。
To conclude, we have delivered an excellent start to fiscal 2027. We are doing what we said we would do, and we are operating with clear strategic and financial priorities, strengthening our core distribution business, expanding our footprint in Specialty and accelerating our other growth businesses. By ruthlessly prioritizing operational excellence and maintaining disciplined capital allocation, we continue to be well positioned for growth and long-term value creation in fiscal 2027 and beyond.
總結來說,我們在2027會計年度取得了非常出色的開局。我們正在做我們說過會做的事,並以清晰的策略與財務優先事項運作:強化核心配送業務、擴大在專科(Specialty)領域的布局,並加速其他成長型業務。透過嚴格優先排序營運卓越並維持紀律性的資本配置,我們持續處於有利位置,可在2027會計年度及更長遠的未來實現成長與長期價值創造。
With that, I will turn it back over to Jason.
接下來,我把時間交回給Jason。
Jason Hollar - Chief Executive Officer, Director
Jason Hollar - Chief Executive Officer, Director
Thanks, Aaron. Beyond the strong quarter, our results continue to reinforce the durability of our business and the important role we play across healthcare, the consistency of our execution and the strength of our customer relationships position us well as we look ahead. Over the last 12 months, we have renewed contracts representing nearly two thirds of our enterprise revenue, the majority of which is long term in length, demonstrating that the value we deliver to customers resonates in the marketplace and provides a stable foundation for continued investment in our business.
謝謝,Aaron。除了本季的強勁表現之外,我們的結果也持續印證我們業務的韌性,以及我們在醫療保健體系中扮演的重要角色;我們執行的一致性與客戶關係的強度,使我們在展望未來時具備良好定位。在過去12個月中,我們已完成續約的合約所代表的營收接近公司整體營收的三分之二,其中多數為長期合約,顯示我們為客戶創造的價值在市場上獲得共鳴,並為我們持續投資於業務提供穩固基礎。
The commercial success spans the enterprise, including renewing our two largest customers in pharma and our two largest customers in GMPD. During this time frame, we've also secured meaningful new business across the other growth businesses. These milestones reflect the consistent service and execution our customers expect from us. And with that backdrop, I want to highlight the progress we're making against several of our strategic priorities.
商業上的成功遍及整個企業,包括與我們在製藥領域的兩大客戶,以及在GMPD領域的兩大客戶完成續約。在此期間,我們也在其他成長型業務中取得了具實質意義的新業務。這些里程碑反映出客戶對我們一貫服務品質與執行力的期待。在此背景之下,我想重點說明我們在多項策略優先事項上的進展。
Beginning with our largest, most significant segment, pharma, once again served as the key contributor to our growth, demonstrating the underlying strength of the business and the effectiveness of the strategic investments we have made. The core distribution business remains durable, and we continue to scale the capabilities that extend our value with providers and biopharma partners.
先從我們最大、最重要的事業部門—製藥(pharma)談起;該部門再次成為成長的關鍵貢獻者,展現了業務的內在韌性,以及我們所做策略性投資的成效。核心配送業務依然穩健,我們也持續擴大相關能力,以提升我們對醫療服務提供者與生物製藥合作夥伴的價值。
The long-term renewal with CVS Health adds to the proof points of our commercial success, following the announced Kroger renewal and our significant new business wins in fiscal '25, including several prominent health systems. The combination has strengthened our core and increase the visibility into the future of the business.
與CVS Health的長期續約,進一步增添了我們商業成功的佐證;此前我們已宣布與Kroger續約,並在2025財年取得多項重要新業務勝利,其中包括數個知名醫療體系。這些組合強化了我們的核心業務,並提升了對未來業務能見度。
This strong position allows us to invest strategically, maintain or improve the high service levels our customers rely on and advance key growth priorities. We also continue to align closely with our manufacturer partners on the evolving pharmaceutical landscape, a collaborative focus highlighted at our recent business partners conference, which convened nearly 500 supplier partners.
這樣的強勢地位使我們得以進行策略性投資,維持或提升客戶所倚賴的高服務水準,並推進關鍵成長優先事項。我們也持續與製造商合作夥伴緊密對齊,以因應不斷演變的製藥產業環境;這種協作重點也在我們近期的商業合作夥伴大會中充分展現,該會議匯聚了近500家供應商合作夥伴。
The breadth of participation reinforces the strategic value of these relationships and our position as the trusted partner across the supply chain. Our Specialty strategy is focused on building connected platforms that help community-based physicians operate more effectively while creating opportunities across data, research and ancillary services.
廣泛的參與度再次印證了這些關係的策略價值,以及我們作為供應鏈中值得信賴合作夥伴的地位。我們的專科(Specialty)策略聚焦於打造互聯的平台,協助社區型醫師更有效率地運作,同時在數據、研究與周邊服務方面創造機會。
The integration of Solaris and our MSO strategy continued to progress during the quarter as we identify synergies between our platforms to strengthen the group with the best of each of the parts. We are heads down approaching this work with discipline and an emphasis on realizing the benefits of greater scale while maintaining a high-quality experience for physicians and patients.
本季Solaris的整合以及我們的MSO策略持續推進;我們正辨識各平台之間的綜效,將各部分的優勢整合,以強化整體。我們正以嚴謹的紀律全力投入此項工作,並著重在實現規模擴大所帶來的效益,同時維持醫師與病患的高品質體驗。
We're all seeing the value of the network beyond practice support. The launch of the INSIGHT-IBD study with Eli Lilly is one example of how our MSO provider relationships, combined with Specialty Networks, real-world data and research capabilities can generate actionable insights for industry partners and support innovation and patient care.
我們都看到了該網絡在診所支援之外的價值。與禮來(Eli Lilly)共同啟動INSIGHT-IBD研究,就是一個例子,說明我們的MSO醫療服務提供者關係,結合專科網絡(Specialty Networks)、真實世界數據與研究能力,如何為產業合作夥伴產出可採取行動的洞見,並支持創新與病患照護。
In biopharma solutions to keep pace with the growing demand, we are expanding 3PL and cold chain capacity through our new St. Louis facility, which we anticipate will start operating by the end of calendar year '27, increasing the breadth and scale of the services we provide.
在生物製藥解決方案方面,為了跟上不斷成長的需求,我們正透過位於聖路易斯(St. Louis)的新設施擴充3PL與冷鏈產能;我們預期該設施將於2027曆年年底前開始營運,進一步提升我們所提供服務的廣度與規模。
We also continue to see success in the cell and gene market, where our 3PL business secured another new exclusive commercialization agreement this quarter to build upon the two new agreements we announced last quarter. Further, our Sonexus patient hub also continued to grow organically, and we remain on track to meet our prior target of doubling the number of therapies supported by fiscal '28, supporting our objective to deepen relationships with biopharma customers across the product life cycle.
我們在細胞與基因市場也持續看到成果;本季我們的3PL業務再取得一項新的獨家商業化協議,延續上季宣布的兩項新協議。此外,我們的Sonexus病患支援中心(patient hub)也持續有機成長;我們仍按計畫達成先前目標,即在2028財年前將所支援的療法數量倍增,以支持我們在產品生命週期各階段深化與生物製藥客戶關係的目標。
In our Global Medical Products and Distribution segment, we continue to execute against our improvement plan, growing Cardinal Health brand and simplifying our operations. As part of this strategy, we recently deployed more than 100 Locus autonomous robots at our Dixon, California, distribution building on the progress we have made over the past couple of years, implementing this AI-enabled technology, which is now in a dozen of our distribution centers.
在全球醫療產品與配送(Global Medical Products and Distribution, GMPD)事業部門,我們持續執行改善計畫,推動Cardinal Health自有品牌成長並簡化營運。作為此策略的一部分,我們近期在加州迪克森(Dixon)的配送中心部署了超過100台Locus自主機器人,延續過去幾年導入這項AI賦能技術的進展;目前該技術已在我們十多個配送中心運行。
This is a tangible example of how we are using technology to simultaneously improve both efficiency and resilience. Cardinal Health brand, Specialty portfolio, which includes our more clinically differentiated products, grew above market and contributed to overall Cardinal Health brand growth in the quarter. Across our other growth businesses, strong industry secular growth trends, combined with disciplined investment in execution are translating into excellent financial outcomes. In at-Home Solutions, we delivered positive results and remain well positioned for continued growth as demand for home-based care expands.
這是一個具體例證,說明我們如何運用科技同時提升效率與韌性。Cardinal Health自有品牌的專科產品組合(Specialty portfolio),其中包含臨床差異化程度更高的產品,本季成長優於市場,並帶動整體Cardinal Health自有品牌成長。在其他成長型業務方面,強勁的產業長期結構性成長趨勢,結合對執行面的紀律性投資,正轉化為優異的財務成果。在居家解決方案(at-Home Solutions)方面,我們交出正向成果,且隨著居家照護需求擴大,我們仍具備持續成長的良好條件。
We have successfully migrated all employees and volume from our recent acquisition of Strive Medical into our nationwide network, further strengthening the platform and reinforcing our strategy to build a scaled, national leader and at-Home care.
我們已成功將近期收購的Strive Medical之所有員工與業務量移轉至我們的全國網絡,進一步強化平台,並鞏固我們打造具規模的全國性居家照護領導者之策略。
In addition, we began construction on our new Sacramento distribution center to support long-term capacity, efficiency and customer service. These initiatives, together with the continued deployment of AI-enabled automation within distribution centers across the network are critical elements of our focus on core operations.
此外,我們已開始興建新的薩克拉門托(Sacramento)配送中心,以支援長期產能、效率與客戶服務。這些舉措,加上在整個網絡的配送中心持續部署AI賦能自動化,是我們聚焦核心營運的關鍵要素。
Nuclear and Precision Health Solutions delivered solid results with continued growth in the core business and strong momentum in PET and theranostics. We remain well positioned to serve the growing pipeline, complex radiopharmaceutical therapies coming to market, including areas like neuroendocrine tumor therapies that we will dispense and distribute.
核醫與精準健康解決方案(Nuclear and Precision Health Solutions)表現穩健,核心業務持續成長,且在PET與放射診療一體化(theranostics)方面動能強勁。面對即將上市、管線日益擴大的複雜放射藥物療法,我們仍具備良好服務能力,其中包括我們將進行調劑與配送的神經內分泌腫瘤療法等領域。
We also continue to invest across our network to drive growth and efficiency, including the rollout of our AI-driven route optimization tool, which is now live in 20 sites and expected to reach all of our 130 radiopharmacies by the end of fiscal. These investments ensure we continue to be an indispensable part of this cutting-edge area of medicine, building on our unmatched geographic reach and service capabilities. Within OptiFreight Logistics, we remain focused on expanding the ways we support our customers, reinforcing and growing our leading value proposition.
我們也持續在整個網絡投資以推動成長與效率,包括推行AI驅動的路線最佳化工具;目前已在20個據點上線,並預期在本財年結束前覆蓋我們全部130家放射藥房。這些投資確保我們持續成為這一前沿醫療領域不可或缺的一環,並在我們無可匹敵的地理覆蓋與服務能力基礎上再接再厲。在OptiFreight Logistics方面,我們仍專注於擴大支援客戶的方式,強化並擴展我們領先的價值主張。
With the launch of our new pharmacy solution in fiscal '26, we are now able to provide better tracking visibility and shipping efficiency be over two dozen pharmacies currently utilizing the technology. The continued improvement and broadening of this suite of services, expands our role in managing our customers' shipping and receiving operations, delivering cost savings for them while also strengthening their resiliency. In addition to meeting a customer need, it also helps prevent disruptions that can ultimately affect patient care.
隨著我們在2026財年推出新的藥局解決方案,我們如今能提供更佳的追蹤可視性與運輸效率,目前已有二十多家藥局正在使用該技術。持續改善並擴充這套服務組合,將擴大我們在管理客戶收發貨作業中的角色,為客戶帶來成本節省,同時也提升其營運韌性。除了滿足客戶需求之外,這也有助於預防最終可能影響病患照護的中斷。
As we look to the balance of the year, we are confident in our outlook, supported by the long-term customer agreements we have secured, the progress we're making across the enterprise and our disciplined execution. With the broad and diverse portfolio and our role as the backbone of healthcare, we are well positioned to navigate the industry's dynamic environment while advancing our priorities around access, affordability and innovation. Our strategy remains clear: strengthen the core, scale Specialty in our growth businesses, improve GMPD and deploy capital with discipline.
展望本年度剩餘期間,我們對前景充滿信心;這份信心來自我們已取得的長期客戶合約、全企業層面的進展,以及我們有紀律的執行。憑藉廣泛且多元的產品組合,以及我們作為醫療體系骨幹的角色,我們具備良好條件在產業動態環境中穩健前行,同時推進我們在可近性、可負擔性與創新方面的優先事項。我們的策略依然清晰:強化核心、在成長型業務中擴大專科(Specialty)規模、改善GMPD,並以紀律方式配置資本。
With that, we will take your questions.
接下來我們開始提問。
Operator
Operator
(Operator Instructions) Erin Wright, Morgan Stanley.
(接線員指示) Erin Wright,摩根士丹利。
Erin Wright - Equity Analyst
Erin Wright - Equity Analyst
Could you unpack the momentum a little bit more on the Pharma Distribution segment? Just more specifically also on the quarterly cadence you gave the detail on renewals in Solaris, which is helpful. But just on an underlying basis, excluding some of those factors, are there any changes that you're seeing in underlying demand trends generics or otherwise that are evolving, maybe better than expected on an underlying basis?
能否再更深入拆解一下製藥配送(Pharma Distribution)部門的動能?更具體來說,也關於你們提到的季度節奏;你們在Solaris續約方面提供了細節,這很有幫助。但若從更底層的角度、排除其中一些因素,你們是否看到基礎需求趨勢(學名藥或其他)有任何變化、正在演進,甚至在基礎面上優於預期?
Jason Hollar - Chief Executive Officer, Director
Jason Hollar - Chief Executive Officer, Director
Erin, thanks for the question. We were really pleased to report the strong Q1 results for the pharma business, really demonstrating the continued momentum that, that business has. As we called out in the prepared remarks, was really driven by the strong unit demand across key product categories, certainly Specialty, certainly generics and indeed, from our largest customers. The Specialty part of our business continues to be quite strong. We saw high teens growth in the quarter, as we called out, certainly a bit above our double-digit expectations that we called from an original guide.
Erin,謝謝你的提問。我們非常高興能報告製藥業務第一季(Q1)的強勁表現,這確實展現了該業務持續的成長動能。如同我們在事先準備的發言中提到的,主要驅動因素是關鍵產品類別的強勁單位需求,當然包括專科(Specialty),也包括學名藥(generics),而且確實也來自我們最大的客戶。我們業務中的專科部分持續相當強勁。如同我們提到的,本季我們看到約十幾個百分點(high teens)的成長,確實略高於我們在原先指引中所預期的雙位數成長。
And importantly, that strength was coming from some key priority areas particularly urology and oncology areas of emphasis for us across the broader portfolio. Also pleased with the positive performance in generics. We saw the strong volume growth, which was a touch above our long-term targeted levels, consistent market dynamics and very driven really by the resilient Red Oak performance. I would be remiss if I didn't also call out the strong operational execution by our management team, really in service of our customers.
而且重要的是,這股強勁動能來自幾個關鍵優先領域,特別是泌尿科與腫瘤科,這些都是我們在更廣泛產品組合中著力的重點。我們也對學名藥的正向表現感到滿意。我們看到強勁的出貨量成長,略高於我們長期目標水準;市場動態一致,而這主要是由具韌性的 Red Oak 表現所驅動。如果我不特別點出管理團隊強勁的營運執行力——真正是為了服務我們的客戶——那就太失禮了。
And so we are quite pleased with how the quarter resulted. From an M&A perspective, the Solaris integration remains on track, right? The results so far are at least as good as our business case in the quarter. And while we did do a couple of ancillary acquisitions, there was not a new contribution, so to speak, from an M&A perspective. We continue to be disciplined and focusing on the integration in the assets that we've acquired so far. So overall, very pleased from a first quarter perspective, which is really the basis for us then providing the updated guidance for pharma.
因此,我們對本季的結果相當滿意。從併購(M&A)的角度來看,Solaris 的整合仍按計畫進行,對吧?到目前為止,本季的成果至少與我們商業案例(business case)預期一樣好。而雖然我們也做了幾筆附帶性的收購,但從併購角度來說,並沒有新的貢獻可言。我們仍維持紀律,並把重心放在迄今收購資產的整合上。所以整體而言,從第一季的角度我們非常滿意,這也成為我們提供藥品業務更新指引的基礎。
We saw strong demand in the first quarter. And indeed, our guidance going forward assumes that strong demand persists into the rest of the year, right? And we continue to expect some good news. And with respect to generics and goodness with respect to the Specialty growth that we called out before. Now we did call out a couple of factors impacting some timing from a quarterly perspective.
我們在第一季看到強勁需求。而且,往後的指引假設這股強勁需求會延續到今年剩餘時間,對吧?我們也仍預期會有一些好消息。包括學名藥方面的利多,以及我們先前提到的專科(Specialty)成長利多。不過,我們也確實點出了幾個因素,會在季度層面影響部分時點。
We need to keep in mind that the Solaris acquisition, we will lap that in the middle of the second quarter. And as Jason highlighted in the remarks, we did renew the CVS contract, and we do have the impact of the customer contract renewals baked into our guidance as well.
我們需要記住,Solaris 的收購在第二季中段會進入同比基期(lap)。另外,如 Jason 在談話中強調的,我們確實續約了 CVS 合約,而客戶合約續約的影響也已納入我們的指引之中。
Operator
Operator
Elizabeth Anderson, Evercore ISI.
Elizabeth Anderson,Evercore ISI。
Elizabeth Anderson - Analyst
Elizabeth Anderson - Analyst
Maybe not too dissimilar to Erin's question, but maybe focusing on other. If we think about the relative like strength, you obviously talked about Strive closing and the DAS like -- how do we think about that from like a go-forward rate? Are you seeing sort of increased customer acceptance penetration? Are you unifies -- what's driving the strength, exactly is it kind of early deal synergies? Like -- just a little bit more detail on that would be super helpful. And any timing-related issues as well in the year.
可能和 Erin 的問題不太不同,但我想把焦點放在「其他」業務。如果我們思考相對的強勁表現,你們顯然談到 Strive 完成交割以及 DAS——我們該如何從未來的運行水準(go-forward rate)來看待?你們是否看到客戶接受度與滲透率提升?你們是否在整合——到底是什麼在驅動這股強勁,是不是某種早期交易綜效?想請你們再多提供一些細節會非常有幫助。以及今年是否也有任何與時點相關的議題。
Jason Hollar - Chief Executive Officer, Director
Jason Hollar - Chief Executive Officer, Director
Thank you. Appreciate the question. We are delighted with the performance of the three businesses that constitute other for us, at-Home, nuclear precision health and OptiFreight and a little bit of color around each of those. In the at-Home space, we are being very intentional to set that business up for long-term success, reflective of the secular trends, the competitive strength that we are building through our acquisitions as well. We call it smart growth.
謝謝。感謝這個問題。我們對構成「其他」的三項業務——at-Home、核醫精準健康(nuclear precision health)以及 OptiFreight——的表現感到非常滿意,我也分別補充一些說明。在 at-Home 領域,我們非常有意識地把這項業務打造為長期成功的基礎,反映長期結構性趨勢,以及我們透過收購所建立的競爭優勢。我們稱之為「智慧成長」。
And so really pleased with how the team is executing, taking advantage of the organic investments we've been making in our supply chain capabilities as well as then how the acquisitions we've completed, like DG are now rolling into our overall progress. Those plans are on track, and we're realizing the planned synergies there.
因此,我們對團隊的執行方式非常滿意:一方面善用我們在供應鏈能力上的有機投資,另一方面也讓我們已完成的收購(例如 DG)逐步融入整體進展。這些計畫都按軌道進行,我們也正在實現原先規劃的綜效。
We've completed the acquisition of Strive, emphasizing the urology part of our category. That's an important element relative to our enterprise strategy as well. And we're looking forward to completing the Adapt transaction at some point after the turn of the calendar year. But overall, we are on track from an operational build perspective and from an integration perspective within at-Home.
我們已完成 Strive 的收購,強化我們在品類中泌尿科的布局。這也是我們企業策略中很重要的一環。我們也期待在跨過曆年之後的某個時間點完成 Adapt 交易。但整體而言,無論從營運建置或 at-Home 內部的整合角度,我們都在按計畫推進。
The nuclear business, strong revenue growth in both pet and thematic areas where we are very focused -- that is a key part of our strategy going forward. Again, you're very focused in urology. Another key part of our enterprise strategy. And we continue to expand our capacity and our resiliency there really focused on applying the technology to make that business better, as Jason highlighted in his remarks.
核醫業務方面,在 PET 與我們高度聚焦的主題領域(thematic areas)都呈現強勁營收成長——這是我們未來策略的關鍵部分。同樣地,我們也非常聚焦在泌尿科。這也是我們企業策略的另一個關鍵部分。我們持續擴充產能並提升韌性,重點在於運用科技讓這項業務變得更好,如 Jason 在談話中所強調。
And then OptiFreight, just another good business there. We are benefiting from the continued expansion of the capabilities there with existing and new customers as well.
接著是 OptiFreight,這也是另一項表現良好的業務。我們同樣受惠於其能力持續擴張,並在既有與新客戶之間推進。
So from a go-forward perspective, from them, again, what we are predicting or we are calling from a guidance perspective is the secular tailwinds are going to be unchanged. They're going to help us carry through the year. We are anticipating strong demand driven by those leading positions and the investments that I referenced. -- growth will accelerate over the course of the year.
因此,從未來展望來看,我們在指引中所預測或所提出的是:這些結構性順風將維持不變。它們將幫助我們貫穿全年。我們預期在領先地位與我剛提到的投資帶動下,需求將保持強勁。——成長將在一年之中逐步加速。
That's partly driven by higher confidence in our pipeline than our original guidance as well. And I've already referenced the fact that we have a positive view of the impact of the integrations as we carry forward. So all in all, a very positive story for us.
這部分也有一部分是因為,相較於我們原先的指引,我們對管線(pipeline)的信心更高。而我也已提到,隨著我們持續推進,我們對整合帶來的影響持正向看法。總而言之,對我們來說這是一個非常正面的故事。
Operator
Operator
Michael Cherny, Leerink Partners.
Michael Cherny,Leerink Partners。
Michael Cherny - Equity Analyst
Michael Cherny - Equity Analyst
I'm going to ask another Specialty question, but just diving a little deeper in terms of the totality of the pieces coming together. I appreciate you called out the Strive transaction and the importance of urology. Maybe using urology as an example, how do the pieces you have between distribution, MSO, other capabilities drive your level of outperformance?
我想再問一個專科(Specialty)相關問題,但想更深入探討各個拼圖如何整體組合起來。我理解你們提到 Strive 交易以及泌尿科的重要性。或許以泌尿科為例,你們在配送、MSO 以及其他能力之間的組合,如何推動你們的超額表現水準?
I know we're all trying to get to the some of what's been behind some of this recent strength. Is there anything, whether it's urology or other examples you can call out on maybe getting to a one plus one plus one greater than three dynamic?
我知道我們都在試著理解近期這些強勁表現背後的原因。是否有任何例子——不論是泌尿科或其他——你們可以分享,來說明如何達到「一加一加一大於三」的動態?
Jason Hollar - Chief Executive Officer, Director
Jason Hollar - Chief Executive Officer, Director
Yes, sure. I love the question and what you just described is the setup for very much the flywheel, the virtuous cycle, the ecosystem of our Specialty strategy, recognizing that these very specialized therapeutic areas have wide-ranging needs. And Strive is a great example of that. You know that we are the leader in urology across many different parts of our enterprise. The obvious ones are certainly within the pharma business, whether it's distribution or GPO, or certainly more recently with our acquisition of Solaris and fitting into the Specialty Alliance.
是的,當然。我很喜歡這個問題;你剛才描述的正是我們專科策略的飛輪、良性循環與生態系的架構,因為這些高度專業的治療領域有非常廣泛的需求。而 Strive 就是一個很好的例子。你知道,我們在企業的許多不同部分都是泌尿科領域的領導者。最明顯的當然是在藥品業務之內,不論是配送或 GPO,或是更近期我們收購 Solaris 並將其納入 Specialty Alliance。
To your point, within Strive is a great example of their leadership within urology supplies for delivery to patients in their home, of which we already had a very strong presence with urology in at-Home Solutions, and this just further expands upon that. So not only can it bring a greater breadth of products and services to urologists and patients who have urological needs. It also allows us to create this general ecosystem of expertise across the business.
如你所說,Strive 是其在泌尿科用品領域、將產品配送到病患家中的領導者;而我們在 at-Home Solutions 的泌尿科方面本來就有很強的布局,這次則是進一步擴大。因此,這不僅能為泌尿科醫師以及有泌尿科需求的病患帶來更廣泛的產品與服務。也讓我們能在整個業務中建立起這個通用的專業生態系。
The other area that you know that we lead in urology is nuclear. And so there's some direct opportunities like with nuclear now being a very large provider of radiopharmaceutical products to Solaris. But it's also way beyond that. It's also the expertise that when our MSO has an opportunity or a challenge, they've got a direct line to leaders in that space that can help them quickly move to different growth and capabilities. Of course, we do that with all of our customers, but these relationships are even tighter, even quicker.
你知道我們在泌尿科領域領先的另一個面向是核醫。因此,確實存在一些直接的機會,例如目前核醫已成為 Solaris 的放射性藥物產品非常大的供應商。但這也遠不止於此。同時也在於專業能力:當我們的 MSO 遇到機會或挑戰時,他們可以直接聯繫該領域的領導者,協助他們迅速轉向不同的成長方向與能力建置。當然,我們對所有客戶都會這麼做,但這些關係更緊密、反應也更快。
But it's -- even in less glamorous ways, perhaps, some of the medical supplies and GMPD that also have very broad capabilities. This list just keeps going on and on and on. And Specialty Networks is another great example of where we started that business originated in urology Part of the reason we acquired them first in the journey was because of the breadth and the capabilities that they had to enter into new therapeutic areas, but also being the leader in both GPO and other data services for urology.
但即便是——也許以較不那麼光鮮的方式——一些醫療耗材與 GMPD 也同樣具備非常廣泛的能力。這份清單只會一直延伸、一直延伸。而 Specialty Networks 是另一個很好的例子:我們最初開始這項業務時,其起源就在泌尿科。我們在旅程初期先收購他們的部分原因,是因為他們具備進入新治療領域所需的廣度與能力,同時也在泌尿科的 GPO 以及其他數據服務方面居於領導地位。
And they -- now they're expanding further into oncology where we see similar connective tissue, a little bit less mature in terms of all the different touch points. Urology is definitely that example that connects broadly. Each one of these examples I just provided you, I would say it's a series of singles and doubles and not home runs. And so when you hear us talk about it, it's a driver here and there in the enterprise and in the ecosystem. But it's rarely the driver, the primary driver.
而他們——現在正進一步擴展到腫瘤科,我們在那裡也看到類似的連結,但就所有不同接觸點而言成熟度稍低一些。泌尿科絕對是那個能夠廣泛連結的典型例子。我剛才提供的每一個例子,我會說是一連串的一壘安打與二壘安打,而不是全壘打。因此當你聽到我們談論這件事時,它是在企業與生態系中這裡一點、那裡一點的驅動因素。但它很少是那個驅動因素、主要驅動因素。
It's a component amongst many others, and that's what this team is focused on is the rising tide of demand and utilization growing and making sure that we're providing solutions to customers and ultimately to patients so that we help close the loop on that service and we can use the full value of all the components of our business to drive the business but also to solve patient needs.
它只是眾多要素中的一個組成部分;而這個團隊所聚焦的,是需求與使用量上升的趨勢,並確保我們為客戶、最終也為病患提供解決方案,讓我們能在服務上形成閉環,同時運用我們業務各個組成部分的完整價值來推動業務成長,也解決病患需求。
Operator
Operator
George Hill, Deutsche Bank.
George Hill,德意志銀行。
George Hill - Analyst
George Hill - Analyst
Jason, one, I ask you to kind of dive in on some recent news is the OPPS rule was finalized last night with the reimbursement changes to 340B. I know that you guys have called out provider strength recently as it relates to revenue growth in the North American pharma business. We'll just be interested in how you think this reimbursement change impacts the provider space? And like whether or not it benefits your MSOs, particularly as a result of a mix shift as volumes in that direction?
Jason,我想請你深入談談一些最新消息:OPPS 規則昨晚定案,其中包含對 340B 的給付變更。我知道你們最近提到,北美藥品業務的營收成長與醫療提供者端的強勁表現有關。我們很想了解你認為這項給付變更會如何影響醫療提供者端?以及它是否會讓你們的 MSO 受益,特別是如果因為量能往那個方向移動而帶來組合轉移?
Jason Hollar - Chief Executive Officer, Director
Jason Hollar - Chief Executive Officer, Director
Yes. It's a great question, George, because I think you teed up the right way where ultimately, these are needs by patients. It's a matter of where does the volume go. And the providers at the end of the day for OPPS, the health, the hospitals, that's something they're going to have to work through. And of course, we're doing whatever we can to help support them if there are instances where they find that less affordable to serve those patients, then we do believe those patients will go elsewhere.
是的。這是個很好的問題,George,因為我認為你切入的方式很對:歸根結底,這些都是病患的需求。問題在於量會流向哪裡。而就 OPPS 而言,最終的提供者——醫療體系、醫院——這是他們必須自行消化與因應的事情。當然,如果有些情況使他們發現服務這些病患的可負擔性降低,我們會盡我們所能支持他們;那麼我們確實相信這些病患會轉往其他地方。
And given our fair share of market across other aspects of the industry, we anticipate picking up that volume consistent with that. That's an assumption and an expectation. We think it's a logic one. We don't know how much it may move around within the industry, but it's something that we would anticipate participating in appropriately, but I think it's a little premature to predict how much in the qualification of that. We'll certainly be watching this very closely, though.
鑑於我們在產業其他面向也擁有相當的市占,我們預期會相應地承接那部分量。那是一個假設與預期。我們認為這在邏輯上是合理的。我們不知道在產業內部會有多少重新分配,但這是我們預期會以適當方式參與的事情;不過我認為現在就去預測其幅度並加以量化,仍稍嫌過早。但我們肯定會非常密切地觀察。
Operator
Operator
Allen Lutz, Bank of America.
Allen Lutz,美國銀行。
Allen Lutz - Analyst
Allen Lutz - Analyst
I want to follow up on Mike's question around urology. It's really nice to see the strong contributions from urology to Specialty growth. I know that Solaris and typical urology practices only about 40% of revenue comes from medications, but that's been clear for your strategy. Would love to dig in more about how the pipeline to add more urologists progressing. What do they care about? And how is pitching to that type of physician different than maybe an oncologist or another type of physician?
我想延續 Mike 關於泌尿科的問題。很高興看到泌尿科對 Specialty 成長有強勁貢獻。我知道 Solaris 與典型泌尿科診所的營收中,只有大約 40% 來自藥品,但這一直很符合你們的策略。我很想更深入了解:新增更多泌尿科醫師的管線進展如何?他們在意什麼?而向這類醫師推介(pitch)的方式,與腫瘤科醫師或其他類型醫師相比,有何不同?
Jason Hollar - Chief Executive Officer, Director
Jason Hollar - Chief Executive Officer, Director
Yes. Let me start with where they are similar. At the end of the day, especially community physicians do what they do for a pretty particular reasons. They want to take care of patients. They want to do so in their community and have that type of relationship. And that means that they're having the challenge of having that connection with their patients while also running a business. And I think more and more, the community physicians see that they need some type of partnership through that process.
是的。我先從相似之處談起。歸根結底,尤其是社區型醫師之所以從事他們的工作,是出於相當明確的原因。他們想照顧病患。他們希望在自己的社區中提供照護並建立那樣的關係。這也意味著,他們在與病患維持連結的同時,還要經營一門生意,面臨挑戰。我認為越來越多社區醫師看到,他們在這個過程中需要某種形式的合作夥伴關係。
So we continue to see that across all of these, especially more complex therapeutic areas where you have wide-ranging needs beyond just distribution and contracting support. But really getting deep into data and analytics. And of course, all of the back office and physician-specific requirements in the ancillary services, this is all very difficult to run a business while also taking care of patients.
因此,我們持續在所有這些領域看到這種趨勢,尤其是在更複雜的治療領域中,你的需求遠不只是配送與合約支持。而是要真正深入數據與分析。當然,還有所有後台作業,以及在輔助服務中與醫師相關的特定要求——在照顧病患的同時要把生意經營好,這一切都非常困難。
And so that urology, I think, is very similar to the other areas that we prioritize, whether that is oncology or autoimmune, they have a complex enough business requirements and complex enough conditions that they're treating with their patients that they do need support of some sort.
因此我認為泌尿科與我們優先聚焦的其他領域非常相似,不論是腫瘤科或自體免疫;他們的業務需求足夠複雜,且所治療的病患病況也足夠複雜,因此確實需要某種形式的支持。
We don't go into urology with a one-size-fits-all type of approach. We look at what is specific on those services. We see urology fits nicely in between oncology and autoimmune. Many of the ancillary services fit one or the other, and there's not much in urology that's not also either in autoimmune or in oncology. So we see that the breadth of capabilities that we bring and the expertise that we bring across those different therapeutic areas allows those urologists to have it always to have it able to take care of the patient, but also to run a successful business.
我們不會以一體適用(one-size-fits-all)的方式切入泌尿科。我們會看這些服務的特定需求是什麼。我們認為泌尿科很適合地介於腫瘤科與自體免疫之間。許多輔助服務要嘛偏向其中之一,而泌尿科中幾乎沒有什麼不是同時也存在於自體免疫或腫瘤科的。因此我們看到,我們在不同治療領域所帶來的能力廣度與專業,使這些泌尿科醫師能夠始終有能力照顧病患,同時也能成功經營業務。
So it's an all along lead up to say that the message absolutely resonates with urologists. And we have a very active, robust pipeline. And we -- in our comments, highlighted that we're very focused on making sure we get this integration right. So if we have a strong foundation to then further build well into the future. It is a space that continues to be quite fragmented.
所以綜合以上鋪陳要說的是:這個訊息絕對能引起泌尿科醫師的共鳴。而且我們有非常活躍、強健的管線。我們——也在評論中強調——非常專注於確保把整合做對。如此一來,我們就能建立堅實基礎,進而在未來持續擴建。這個領域仍然相當分散。
It is much more fragmented than oncology, a little bit more consolidated in autoimmune, but more closely related to autoimmune than it is to oncology. So there's a lot of potential opportunities for consolidation, we will have opportunities to consolidate further. Our constraint is very much on our confidence that we will integrate it very successfully, so the physicians have a fantastic experience in the process.
它比腫瘤科分散得多;相較之下,自體免疫領域更集中一些,但泌尿科與自體免疫的相似度比與腫瘤科更高。因此在整併方面有很多潛在機會,我們也會有機會進一步整併。我們的限制主要在於:我們必須有信心能非常成功地完成整合,讓醫師在過程中獲得極佳的體驗。
Operator
Operator
Lisa Gill, JPMorgan.
Lisa Gill,摩根大通。
Lisa Gill - Analyst
Lisa Gill - Analyst
I appreciate your comments around 340B and the potential and change inside of care. Obviously, with the very dynamic environment right now. How should we think about any potential changes or things that you're watching from a DC perspective, as we think about reimbursement going forward, you've highlighted WAC changes and your ability to be able to manage through that. But anything that's on your radar that you're looking at from that perspective as we think going into calendar '27?
感謝您對 340B 以及照護體系內部潛力與變化的評論。顯然,在目前非常動態的環境下。從華府(DC)的角度來看,當我們思考未來的給付/報銷(reimbursement)走向時,對於任何潛在變動或您正在關注的事項,我們應該如何看待?您已強調 WAC 的變動以及您有能力因應。但從這個角度來看,當我們展望進入 2027 年曆年時,是否有任何在您雷達上的事項是您正在關注的?
Jason Hollar - Chief Executive Officer, Director
Jason Hollar - Chief Executive Officer, Director
Yes. Well, we're always looking at everything, I guess, is probably the short answer. When I think about regulatory, I start with nearly the same starting point no matter what particular topic we're talking about. Number one, we do not believe it's the intention -- and this is getting off 340B a little bit, I'll get back to it in a second. But just regulatory, more general, you commented about D.C. Where there's the most implication typically is at the provider level. And of course, where we are the provider is normally within the MSOs in those community physicians.
是的。嗯,我想簡短的答案大概是:我們一直在看所有事情。談到監管時,不論我們在談哪個特定主題,我幾乎都會從相同的起點開始。第一,我們不認為政府的意圖是——這裡先稍微離開 340B 一下,我等一下再回來。但就更一般性的監管而言,您提到華府(D.C.)。通常影響最大的地方是在醫療提供者(provider)層級。而當然,我們作為提供者的角色通常是在那些社區醫師的 MSO 之中。
So in those instances, we do not believe the intention of the administration as to harm that community provider. Our goal and objectives are very aligned with the administration, very aligned with those physicians. We're looking for greater access to low-cost innovative healthcare. And we don't think it's their intention to harm what is now the lowest cost form of care already in those communities, of course, the access to those communities.
因此在那些情況下,我們不認為政府的意圖是要傷害社區端的提供者。我們的目標與宗旨與政府高度一致,也與那些醫師高度一致。我們追求的是讓更多人能取得低成本、具創新性的醫療照護。我們不認為他們的意圖是要傷害目前在這些社區中已經是最低成本的照護形式,當然也包括對這些社區的可近性。
So first and foremost, we don't believe that, that is the objective and the intent. And then secondly, even if there are implications to those providers, those physicians, it is usually a second order effect for us. Again, while we have the direct impact for some therapeutic areas, where we participate typically has a very diverse payer set very substantial portion of our business with commercial payers, and we have very diversified drug spend and other types of revenue within those MSOs and those providers.
所以首先,我們不認為那是目標與意圖。其次,即便對那些提供者、那些醫師真的產生影響,對我們而言通常也是第二層次的影響。同樣地,雖然在某些治療領域我們會受到直接影響,但我們參與的領域通常擁有非常多元的付款方組合(payer set),我們相當大一部分業務來自商業保險付款方,而且在那些 MSO 與提供者體系內,我們的藥品支出與其他類型收入也非常分散。
So we have a relatively low potential impact, even if there is legislation that ends up impacting those providers, which, again, we don't think is likely to be the case. So -- there's a lot of potential variables that happen with that. And of course, we are in D.C. a lot. We are very closely engaged both with both sides of the aisle.
因此,即使最終真的有立法影響到那些提供者,我們的潛在影響也相對較低——而且我們再次強調,我們不認為那很可能會發生。所以——這裡面有很多可能的變數。當然,我們也經常在華府(D.C.)。我們與兩黨都保持非常密切的互動。
Of course, we had long-standing relationships. We continue to have long-standing relationships. There are some new members of Congress that we're going to now need to spend a little bit more time with, but -- the vast majority of the people we see are still same people, and we'll continue to make sure that we're advocating not just for our business but ultimately for customers and the patients.
當然,我們有長期建立的關係。我們也會持續維持這些長期關係。國會裡有一些新成員,我們接下來需要花更多時間與他們交流,但——我們見到的大多數人仍然是同一批人;我們也會持續確保我們所倡議的不只是我們的業務,最終更是為了客戶與病患。
As it relates to the 340B, I think, conceptually, a lot of those things carry over with that. The only thing I'd add specifically about any specific product category that would be outside of the private space now thinking about us as a distributor, you've seen our consistent ability to migrate through that.
至於 340B,我認為概念上,許多上述觀點同樣適用。我唯一要補充的是,若談到某些特定產品類別、且不在目前私營領域之內、而是把我們視為一個經銷商(distributor),您已經看到我們一貫有能力在那樣的環境中持續調整與推進。
Sometimes there may be a little bit of a timing differential in terms of when certain corridors are touched and when those impacts can then be passed on to customers. But end of the day, we provide huge value for the services that we provide, and we would anticipate that the continued compensation would be appropriate for that.
有時在時點上可能會有些差異,例如某些「區間/走廊」(corridors)何時被觸及,以及那些影響何時能轉嫁給客戶。但歸根結底,我們為所提供的服務創造了巨大的價值,我們也預期對此能持續獲得適當的報酬。
Operator
Operator
Eric Percher, Nephron Research.
Eric Percher,Nephron Research。
Eric Percher - Analyst
Eric Percher - Analyst
A question on generic program performance. I believe we heard volume running a bit ahead of your expectations, and that continues on, but there was also a comment on Red Oak. And so I wanted to ask if the Red Oak benefits tend to continue to accumulate over time. Is there any change relative to extending the distribution agreement? Or does Red Oak continue to extend through 2029?
我有一個關於學名藥(generic)專案表現的問題。我相信我們聽到的訊息是,出貨量(volume)略高於你們的預期,而且這個趨勢仍在延續,但也提到了 Red Oak。所以我想問,Red Oak 的效益是否通常會隨時間持續累積?在延長配銷協議方面是否有任何變化?或者 Red Oak 仍會延續到 2029 年?
Jason Hollar - Chief Executive Officer, Director
Jason Hollar - Chief Executive Officer, Director
Yes. Well, I will never speak for our customer, but I'm pretty confident they speak very highly of -- I should say, our joint venture partner, in this case, speak very highly of the value that we receive from Red Oak, not just in terms of value in dollars and cents, but in terms of the service levels, we continue to believe we're best-in-class with.
是的。嗯,我永遠不會替我們的客戶發言,但我相當有信心他們對——我應該說,在這個案例中,我們的合資夥伴——他們對我們從 Red Oak 獲得的價值評價非常高,不僅是以金錢衡量的價值,也包括我們持續相信自己在服務水準上屬於同業最佳(best-in-class)。
So -- yes, Red Oak is a separate contract that will certainly be looking to address relatively soon. It's a relationship that goes back a long way, and we see that there is continued value. So your question on ongoing value, it's an evergreen opportunity. While -- and again, it goes to value in terms of dollars as well as service level, there's opportunities for Red Oak to perform every single day. There's always going to be opportunities in the marketplace to improve service.
所以——是的,Red Oak 是一份獨立合約,我們當然會在相對不久的將來著手處理。這是一段延續很久的合作關係,我們看到其價值仍在延續。因此您問到持續性的價值,它是一個可長期延續的機會(evergreen opportunity)。同樣地——而且再說一次,價值不僅在於金額,也在於服務水準——Red Oak 每一天都有機會展現績效。市場上永遠都會有改善服務的機會。
There will be manufacturers coming in and out of market, and it's their objective to bring us the best value, the best cost, the best service. And as those new items, which is an opportunity for the industry and for ourselves in particular, the loss of exclusivity, new items this year is pretty good. It's fairly consistent to what we saw last year. We see an increasing pipeline building over the next couple of years. So we see additional opportunity for Red Oak to provide value to both of their parents there.
會有製造商進出市場,而他們的目標是為我們帶來最佳價值、最低成本與最佳服務。而隨著這些新項目出現——這對產業以及對我們自身而言都是機會——今年的專利到期/失去獨占(loss of exclusivity, LOE)帶來的新項目相當不錯。這與我們去年看到的情況相當一致。我們看到未來幾年管線正在增加。因此我們看到 Red Oak 有更多機會為其兩個母公司(parents)提供價值。
And it's our expectation that, that relationship certainly would transcend any spin-off on the CVS side, but then certainly, we would anticipate it proceeding beyond the '29 time frame as well. But we have a little bit of work to do to complete that step.
我們的預期是,該合作關係當然會超越 CVS 端任何可能的分拆(spin-off),而且我們也預期它會在 2029 年之後繼續延伸。不過我們還需要做一些工作來完成那一步。
Aaron Alt - Chief Financial Officer
Aaron Alt - Chief Financial Officer
Just to jump on top of that briefly. Eric, from a guidance perspective, Jason referenced that the LOE benefits year-over-year for '27, which were in are roughly consistent with what they were last year. We will see a nice benefit, particularly in '29, going forward as we look at the number of LOEs that are coming. And so just want to be clear on that from a long-term perspective.
我再就此簡短補充一下。Eric,從財測(guidance)的角度,Jason 提到 2027 年的 LOE 年對年效益,大致與去年相當一致。而展望未來,特別是在 2029 年,隨著即將到來的 LOE 數量增加,我們會看到相當不錯的效益。所以只是想從長期角度把這點說清楚。
Operator
Operator
Kevin Caliendo, UBS.
Kevin Caliendo,瑞銀(UBS)。
Kevin Caliendo - Analyst
Kevin Caliendo - Analyst
Wanted to talk a little bit about like future M&A plans. You highlighted Specialty and the like. But when we're thinking about this -- is it market share? Is it more services? Would you be interested in sort of following suit with McKesson and maybe adding some clinical trial opportunities for your urology GPO network? Or -- and maybe there's stuff to do in the home? I guess what I'm asking is where do you feel like there's opportunity to grow? What would be a leverageable asset for you in either of these venues?
我想談談未來的併購(M&A)計畫。你們強調了 Specialty 等領域。但當我們思考這件事時——你們追求的是市占率嗎?還是更多服務?你們是否有興趣仿效 McKesson,例如為你們的泌尿科 GPO 網路加入一些臨床試驗(clinical trial)相關機會?或者——也許在居家(home)領域也有一些事情可做?我想問的是,你們覺得哪裡有成長機會?在這些場景中,對你們而言什麼會是可槓桿化(leverageable)的資產?
Jason Hollar - Chief Executive Officer, Director
Jason Hollar - Chief Executive Officer, Director
Sure. I love the question, and happy to go deeper. First of all, what's really important to us with any M&A you start with, you lead with the strategy. And I think it's highly likely that anything that we do in the future, you'll see connective tissue to the broader strategy that we've laid out in good detail. And somewhat at least consistent with the work that we've done before.
當然。我很喜歡這個問題,也很樂意再深入說明。首先,對我們而言,任何併購(M&A)最重要的是從策略出發、以策略為先。我認為,我們未來所做的任何事情,你都很可能會看到它與我們已經相當詳細闡述的整體策略之間的連結。而且至少在某種程度上,會與我們過去所做的工作保持一致。
And that's because not only is that the best way to create value by executing well being tight with that strategy. There's such opportunity within the current realm of total addressable market that we have today that I think it's highly likely that we're going to want to continue to stay focused. So for -- to be very clear, we're not looking for a fourth leg of the stool, but there's still a lot of additional opportunities within the other three legs that we have today.
這是因為,緊扣策略並把執行做好,是創造價值的最佳方式。在我們目前所面對的整體可服務市場(TAM)範疇內,仍有非常多的機會,因此我認為我們很可能會希望持續保持聚焦。所以——說得非常清楚——我們並不在尋找「第四條腿」,但在我們現有的另外三條腿之內,仍然有很多額外的機會。
And another thing I'll just say, a little bit of an editorial on this. Our answer could be very different than our competition's answer, and we all could be right. What I mean by that is we have different strengths. We have different -- of course, we all have a similar core, but we have different areas that we are leaders in.
另外我也想補充一點,算是我個人的一些評論。我們的答案可能會與競爭對手的答案非常不同,而我們彼此也都可能是對的。我的意思是,我們各自有不同的優勢。我們有不同的——當然,我們都有相似的核心,但我們在不同領域是領導者。
When you look at within our Specialty business, what we have with Specialty Alliance, our focus on the multi-specialty and all the investments we've made there with biopharma solutions, they have similar types of services there, but they don't necessarily overlap in exactly the same way. And so we have some strength there. And of course, we have our other growth businesses of nuclear at-Home and OptiFreight that are leaders in their space. and also quite unique relative to the competition.
當你看我們的專科(Specialty)業務,例如我們的 Specialty Alliance、我們對多專科的聚焦,以及我們在生物製藥解決方案上的各項投資,他們也有類似類型的服務,但不一定在完全相同的方式上重疊。因此我們在那裡有一些優勢。當然,我們還有其他成長型業務,例如居家核醫(nuclear at-Home)與 OptiFreight,在各自領域都是領導者,相較於競爭對手也相當獨特。
So we could end up having a different answer. They could go deeper in a particular area, and it may or may not be where we want to focus on. So where are we going to focus? It's going to be a lot of the same themes that you've heard from the Specialty, absolutely. Within Specialty, we do see continued opportunity within the MSOs.
所以我們最後可能會有不同的答案。他們可能會在某個特定領域更深入,而那可能是、也可能不是我們想要聚焦的方向。那我們會聚焦在哪裡?會有很多你從專科業務聽過的相同主題,絕對如此。在專科領域內,我們確實看到在 MSO(醫師診所管理組織)方面仍有持續的機會。
As I just indicated, where we have prioritized within our MSOs, it remains a more fragmented space, and we are starting to consolidate that, but there's still a lot of opportunity there. Outside of the MSOs within biopharma solutions, we highlighted our leadership in areas like our 3PL like our Sonexus patient hub.
如我剛才所提到的,在我們已優先布局的 MSO 領域,這仍是一個更為分散的市場;我們正在開始進行整合,但那裡仍有很多機會。在生物製藥解決方案中、MSO 之外的部分,我們也強調了我們在例如 3PL(第三方物流)以及 Sonexus 病患服務中心(patient hub)等領域的領導地位。
These are areas that we are the leader, and we have some opportunity because it's still, in many cases, fragmented and with good opportunity. But there's a broad need by customers that's not always being satisfied in the marketplace to their desires, and we see more opportunity there. And then within the other growth businesses where we've been most active has been in at-Home Solutions, also very fragmented space.
這些領域我們是領導者,而且因為在許多情況下仍然相當分散,所以我們仍有一些機會。但客戶有廣泛的需求,在市場上並不總是能以他們期望的方式被滿足,我們在那裡看到更多機會。此外,在其他成長型業務中,我們最積極的領域是在居家解決方案(at-Home Solutions),那同樣是一個非常分散的市場。
So the word fragmented came up in most everything I talked about, and that just tells you that there's a lot of opportunity, a lot of potential partners there, and it can be a partnership. It doesn't have to be an acquisition. But there's enough on that list that I suspect you're going to -- that's where we spend the most time is where we spend all of our dollars is in areas that hit those particular parameters to date, and it's where we are most focused in our investigations and our exploratory discussions in the marketplace today.
所以我談到的大多數事情都出現了「分散」這個詞,這告訴你那裡有很多機會、很多潛在合作夥伴,而且可以是合作關係,不一定要是收購。但在那份清單上有足夠多的項目,我猜想你會看到——我們花最多時間、也投入所有資金的地方,就是迄今為止符合那些特定參數的領域;同時,這也是我們目前在市場上進行調查研究與探索性洽談時最聚焦的方向。
So our objective is consistent with the strategy. Therefore, it should not be a surprise whatever we choose to do. We have the financial flexibility to do so, but we also have a lot of confidence in the course. So we'll be ready to execute financially and with the support organization when the opportunity presents.
因此,我們的目標與策略是一致的。所以無論我們選擇做什麼,都不應該令人意外。我們具備這麼做的財務彈性,但我們也對既定路徑非常有信心。因此,當機會出現時,我們會在財務面以及支援組織面都準備好執行。
Aaron Alt - Chief Financial Officer
Aaron Alt - Chief Financial Officer
I want to emphasize on that. Jason's use of the word flexibility is really driven by the strong cash flow generation that the business has been able to deliver for the last several quarters. You will have seen that we had another quarter of great adjusted free cash flow, $5.3 billion of cash in the bank at the end of our first quarter. But in all of that, we will remain loyal to our disciplined capital allocation philosophy, right? We are investing all the dollars that we need to ensure from an organic CapEx perspective.
我想強調這一點。Jason 使用「彈性」這個詞,主要是來自於公司在過去幾個季度所展現的強勁現金流創造能力。你也看到我們又交出了一個調整後自由現金流表現很好的季度,第一季末銀行帳上現金達 53 億美元。但在這一切之中,我們仍會忠於我們嚴謹的資本配置理念,對吧?從有機資本支出(CapEx)的角度,我們會投入所有必要的資金以確保相關需求。
We feel great about the breadth of our investments more than we ever have before across the businesses, really all five of our operating businesses. We've got a great, strong balance sheet. We're within our targeted leverage ratio. So we don't need to take actions there to protect it. You saw we repurchased half of our annual commitment of share repurchase of $1 billion.
我們對投資布局的廣度感到非常振奮,跨越各項業務,這種感受比以往任何時候都更強烈——實際上涵蓋我們全部五個營運事業。我們有一張非常強健的資產負債表。我們的槓桿比率在目標區間內。因此我們不需要採取行動來保護它。你也看到我們已回購了年度 10 億美元庫藏股承諾的一半。
We repurchased $500 million in the first quarter, and really putting us in a place where we can consider what next from that strong cash flow, whether it's the incremental M&A that Jason was just referencing or for the return of capital to shareholders. So -- we're in a strong place as we carry forward into the rest of the year and are really pleased with the momentum overall.
我們在第一季回購了 5 億美元,這也讓我們站在一個位置上,可以基於強勁的現金流來思考下一步——不論是 Jason 剛提到的額外併購,或是把資本回饋給股東。所以——我們在邁入今年剩餘時間時處於非常強勢的位置,並且對整體動能感到非常滿意。
Operator
Operator
We have reached the end of the Q&A session. I will now hand the call back to Jason Hollar for closing remarks.
問答環節到此結束。我現在把電話交回給 Jason Hollar 作結語。
Jason Hollar - Chief Executive Officer, Director
Jason Hollar - Chief Executive Officer, Director
Yes. Just thanks for joining us. And as always, reach out to David and team for any follow-ups that you may have. Have a great day.
好的。感謝各位加入我們。一如既往,如有任何後續問題,請聯繫 David 及其團隊。祝各位有美好的一天。
Operator
Operator
This concludes today's call. Thank you for attending. You may now disconnect.
今天的電話會議到此結束。感謝各位出席。您現在可以掛線。